Full access
Articles
Published Online: 17 January 2017

Low Rates of HIV Testing Among Adults With Severe Mental Illness Receiving Care in Community Mental Health Settings

Christina Mangurian, M.D., M.A.S., Francine Cournos, M.D., Dean Schillinger, M.D., Eric Vittinghoff, Ph.D., Jennifer M. Creasman, M.S.P.H., Bernard Lee, M.P.H., Penelope Knapp, M.D., Elena Fuentes-Afflick, M.D., M.P.H., and James W. Dilley, M.D.Authors Info & Affiliations
Publication: Psychiatric Services
Volume 68, Number 5
https://doi.org/10.1176/appi.ps.201600248
Track CitationsAdd to favorites
PDF/EPUB

Abstract

Objective:

This research aimed to characterize HIV testing rates among Medicaid recipients with severe mental illness who received public specialty mental health services.

Methods:

This retrospective cohort study examined California Medicaid records from October 1, 2010, to September 30, 2011 (N=56,895). Study participants were between age 18 and 67, utilized specialty mental health care services, were prescribed antipsychotic medications, and were not dually eligible for Medicare. Adjusted Poisson regression models were used to estimate the overall effects of predictor variables on HIV testing prevalence.

Results:

During the study period, 6.7% of people with severe mental illness received HIV testing. Men were 32% less likely to be tested for HIV than women (p<.001). Compared with whites, Asians/Pacific Islanders were 53% less likely and blacks were 82% more likely to be tested (p<.001). Those with comorbid drug or alcohol use disorders were more likely to be tested than those without such disorders (p<.001). Utilization of nonpsychiatric medical care was the strongest predictor of HIV testing (p<.001).

Conclusions:

Most adults with severe mental illness receiving public specialty mental health services were not tested for HIV during a one-year period. Public health administrators must prioritize HIV testing for early identification of HIV infection and prevention of HIV transmission.
Persons with severe mental illness, such as schizophrenia, bipolar disorder, and major depression with psychosis, die 25 years earlier than the general population (1,2). Although most of this mortality is due to cardiovascular disease, two recent meta-analyses found median HIV prevalence rates ranging from 1.8% to 6% (3,4). Although studies reviewed in these analyses were limited by small sample sizes, variable time frames, and variable methods of ascertainment, the prevalence of HIV among persons with severe mental illness is consistently reported to be greater than in the general U.S. population (.5%) and contributes to the early mortality in this population. The increased HIV prevalence among persons with severe mental illness is not likely the result of a psychiatric illness–mediated biological predisposition to HIV but rather appears to be driven by higher rates of HIV-related risk behaviors. For example, people with severe mental illness report higher rates of unprotected sex, injection drug use, substance use in the context of sexual activity, and sexual violence than persons in the general population and a greater likelihood of encountering sexual partners with HIV infection (5–8).
A 2009 systematic review reported that HIV testing rates among people with severe mental illness were low (9). Unfortunately, the review was based on a series of studies with small samples, which resulted in wide ranges of recent (17%−49%) and lifetime (11%−89%) HIV testing rates (9). A recent cross-sectional study evaluated HIV testing among persons with mental illness in the 2007 National Health Interview Survey (10). This study found that those with any mental illness (including depression and anxiety) were more likely than the general population to report ever being tested for HIV (10). Although this was a study of persons with mental illness, the sample size for those with severe mental illness was quite low (N=108 for schizophrenia, and N=292 for bipolar disorder) (10). The small sample sizes in all of these studies reflect the difficulty of examining medical care received by people with severe mental illness because of the segregation of primary care and behavioral health care that is characteristic of the U.S. public health care system (11).
This study filled this gap in the literature by examining a unique data set that combined public mental health and general medical care data for Medicaid enrollees. Because racial-ethnic minority populations have higher rates of HIV than the general population (12,13), the large size of this retrospective cohort also permitted analyses of disparities in HIV testing among racial-ethnic minority populations with severe mental illness. To our knowledge, this is the first large study examining HIV testing among people receiving specialty mental health services.

Methods

Study Design

This retrospective cohort study utilized administrative, pharmacy, and billing data from California Medicaid (Medi-Cal) and the Client and Service Information (CSI) system for the period October 1, 2010, to September 30, 2011. The CSI system is an encounter-based data system that is funded by the state and county and used to track utilization of noninpatient mental health services across California (14). The study was approved by the University of California, San Francisco, Committee of Human Research (11–06939); the State of California Committee for the Protection of Human Subjects (FWA00000681); and the Data and Research Committee of the California Department of Health Care Services (DHCS) (IRB00000552). Following approval, DHCS combined these databases, deidentified the data, and provided a unique data set. Data were made available because we were helping DHCS’s public partners examine the efficacy of a separate statewide quality improvement project.

Population

As of January 1, 2011, 7,505,841 people in California were enrolled in Medicaid (15). The following inclusion criteria generated the study cohort: age ≥18 years and <68, Medi-Cal enrollee, specialty mental health care utilization during the study period, prescription of one or more antipsychotic medications during the study period, and not dually eligible for Medicare. [A list of the prescribed antipsychotic medications is available in an online supplement to this article.] Of note, prescription claims for antipsychotic medications were used to define the cohort for a parent study examining diabetes screening (16). In California eligibility for specialty mental health care is limited to individuals who meet medical necessity criteria by being diagnosed as having a “serious and disabling mental disorder” (17). The dually eligible population was excluded because Medicare laboratory billing data (which supersedes Medicaid data) were unavailable. We were not able to exclude people living with HIV; DHCS would not provide this level of data because of confidentiality concerns.

Measures

The primary outcome measure was evidence of HIV-1 or HIV-2 antibody testing (CPT codes 86701, 86702, 86703, 87390, or S3645). The U.S. Preventive Services Task Force recommends annual HIV testing for populations at highest risk (men who have sex with men and active injection drug users) and testing every three to five years for those at increased risk of HIV infection (having unprotected vaginal or anal intercourse; having sexual partners who are HIV infected, bisexual, or injection drug users; or exchanging sex for drugs or money) (18). Because people with severe mental illness are much more likely than the general population to fall into the categories of either highest risk or increased risk (5–8), we determined that a year-long period was a reasonable time frame to examine evidence of HIV testing. The database included additional variables: age, gender, race-ethnicity, county, antipsychotic medications, and nonpsychiatric medical office visits (new patients, CPT codes 99201–99205; established outpatients, 99211–99215; and other outpatient consultations, 99241–99245). All axis I diagnoses of mental and substance use disorders were collected from the CSI system and determined by mental health providers. Axis I diagnoses of mental disorders (not including substance use disorders) were hierarchically categorized as follows: schizophrenia spectrum disorder, bipolar disorder, major depressive disorder, anxiety disorder, and other. Counties were dichotomized into rural or urban according to 2013 National Center for Health Statistics definitions (19).

Statistical Analysis

Adjusted Poisson regression models were used to estimate the overall effects on prevalence of HIV testing of gender, race-ethnicity, age group, county type (rural versus urban), diagnosis, and history of use of substance use disorder treatment and nonpsychiatric outpatient health care. We used a directed acyclic graph to identify confounders and mediators of each predictor. Models specific to each predictor of interest were used to estimate overall effects by adjusting for common causes of each predictor and HIV testing (confounders) but excluding factors on the causal pathway between them (mediators) (20). Models excluding confounders would provide biased estimates, whereas models including mediators would at best estimate direct effects via other pathways. Poisson regression was used as the best approximation of prevalence ratio.
Because mental health service delivery is realigned from the state to the county levels in California, we used robust standard errors to account for clustering of outcomes by county and to accommodate the use of a Poisson model for a binary outcome (Stata version 13.2) (20). Seven rural counties (12%) had few observations and were grouped with counties of similar size, region, and demographic characteristics (19). For example, we aggregated data from three rural counties: Alpine, Inyo, and Mono. We excluded data from San Mateo County, because we did not have access to the separate county pharmacy billing system that would identify the cohort taking antipsychotic medications.

Results

This study cohort represented .76% of all Medicaid recipients in California in 2011 (N=56,895 of 7,505,841). Over a year-long period, 6.7% (N=3,815) of study participants received HIV testing. Table 1 shows differences in the characteristics of participants who did and did not receive HIV testing. Table 2 shows the unadjusted and adjusted relative risk of HIV testing in relation to various predictor variables.
TABLE 1. Characteristics of California Medi-Cal enrollees receiving care in community mental health clinics, 2010–2011, by HIV testing status
 Total (N=56,895)HIV testinga (N=3,815)No HIV testing (N=53,080) 
CharacteristicN%N%N%p
Sex      <.001
 Male25,58744.91,4055.524,18294.5 
 Female31,30855.02,4107.728,89892.3 
Race-ethnicity      <.001
 Asian/Pacific Islander7,19712.61952.77,00297.3 
 Black11,03819.41,19710.89,84189.2 
 Hispanic11,24819.88127.210,43692.8 
 Other5,91310.43215.45,59294.6 
 White21,49937.81,2906.020,20994.0 
Ageb      <.001
 18–278,91115.77057.98,20692.1 
 28–4724,02142.21,8797.822,14292.2 
 48–6723,96342.11,2315.122,73294.9 
County type      .541
 Rural1,6112.81237.61,48892.4 
 Urban55,28497.23,6926.751,59293.3 
Diagnosisc      <.001
 Anxiety disorder2,1283.71165.42,01294.6 
 Bipolar disorder8,12614.36948.57,43291.5 
 Major depressive disorder12,92722.78516.512,07693.5 
 Other3,9677.02195.53,74894.5 
 Schizophrenia spectrum disorder29,74752.31,9356.527,81293.5 
Comorbid drug or alcohol use disorder10,12717.89719.69,15390.4<.001
Evidence of use of general medical care37,37465.73,0658.234,30991.8<.001
a
Evidence of receipt of HIV test in the past year
b
Categories were those provided by the California Department of Health Care Services.
c
Axis I diagnoses were hierarchically categorized as follows: schizophrenia spectrum disorder, bipolar disorder, major depressive disorder, anxiety disorder, and other.
TABLE 2. Relative risk (RR) of HIV testing among California Medi-Cal enrollees with severe mental illness (N=56,895) and receiving care in community mental health clinics, 2010–2011
 Unadjusted RRAdjusted RR (ARR)a
CharacteristicRR95% CIPairwise ppARR95% CIPairwise pp
Male (reference: female)b.71.62–.82<.001<.001.68.58–.80<.001<.001
Race-ethnicity (reference: white)b   <.001   <.001
 Asian/Pacific Islander.45.38–.54<.001 .47.40–.55<.001 
 Black1.811.39–2.35<.001 1.821.41–2.35<.001 
 Hispanic1.201.08–1.34.001 1.151.03–1.29.017 
 Other.91.77–1.07.238 .93.81–1.08.361 
Age (reference: 18–27)b,c   <.001   <.001
 28–47.99.87–1.13.866 .95.82–1.09.459 
 48–67.65.51–.82<.001 .63.50–.80<.001 
Rural county type (reference: urban)b1.14.74–1.76.541.5411.23.85–1.78.276.276
Diagnosis (reference: schizophrenia spectrum disorder)d   <.001   <.001
 Anxiety disorder.84.69–1.02.076 .90.76–1.08.269 
 Bipolar disorder1.321.21–1.43<.001 1.161.05–1.29.003 
 Major depressive disorder1.01.92–1.11.797 1.02.94–1.11.610 
 Other.85.69–1.04.105 .85.72–.99.038 
Comorbid drug or alcohol use disorder (reference: no)e1.591.43–1.74<.001<.0011.471.37–1.58<.001<.001
Evidence of health care use (reference: no)f2.131.73–2.63<.001<.0012.291.87–2.80<.001<.001
a
A directed acyclic graph was used to summarize the a priori hypotheses for the causal relationships among the variables in the analysis and then used to identify the confounders and mediators of the relationship of each variable to HIV testing. The model for each relationship included the identified confounders and excluded the mediators.
b
Controlled for three main demographic variables (sex, race-ethnicity, and age) and county type, unless the variable was the predictor variable of interest
c
Categories were those provided by the California Department of Health Care Services.
d
Controlled for main demographic variables, county type, and comorbid substance use disorder
e
Controlled for main demographic variables, county type, and axis I diagnosis
f
Controlled for main demographic variables, county type, axis I diagnosis, and comorbid substance use disorder
After adjustment for potential confounders for each predictor variable (see footnotes in Table 2), men were less likely than women to be tested for HIV (adjusted risk ratio [ARR]=.68 p<.001). In addition, older adults were dramatically less likely than adults ages 18–27 to receive HIV testing (ARR=.63). Compared with rates among whites, HIV testing rates were significantly lower among Asians/Pacific Islanders (ARR=.47, p<.001) but higher among blacks (ARR=1.82, p<.001). No other racial-ethnic disparities in HIV testing were found. There was some variability in HIV testing by psychiatric diagnosis (p<.001).
In contrast, participants with comorbid drug or alcohol use disorders were somewhat more likely than those without such disorders to be tested for HIV (adjusted RR=1.47, p<.001). Participants with evidence of use of nonpsychiatric outpatient medical care were more than twice as likely to be tested for HIV than those who did not use such care (adjusted RR=2.29, p<.001).

Discussion

This large retrospective cohort study of adults with severe mental illness served within California’s public mental health care system generated three main findings that have important public health implications. First, only 6.7% of individuals in this sample received HIV testing during a one-year period—clearly a missed prevention opportunity. This low testing rate is concerning given the high prevalence of HIV risk factors and HIV infection in this population. Best estimates find HIV prevalence among those with severe mental illness to be as much as tenfold higher than in the general U.S. population (3). In addition, despite the high prevalence of HIV risk behaviors among persons with severe mental illness, this testing rate is not much higher than the 2011 self-reported HIV testing rate among California’s general population (5.2%) (21). Because effective treatments for HIV are widely available in the United States and people with severe mental illness appear to adhere to antiretroviral therapy at rates similar to rates in other groups (22), this lack of testing is a missed prevention opportunity to detect HIV early in the course of illness, thus reducing the risk of disease progression to AIDS and preventing its spread to others.
HIV testing is central to national efforts to reduce infection rates, with the hope of eventually eradicating HIV. In 2010, it was estimated that nearly 76% of HIV-positive individuals in the United States knew their HIV status—likely because of 2006 efforts by the Centers for Disease Control and Prevention to increase routine HIV testing (23,24). Because individuals with severe mental illness are much more likely to be at high risk or increased risk of HIV infection compared with the general population (5–8,18) and evidence suggests that there is room to improve regarding obtaining sexual risk histories (25,26), we believe that annual HIV testing should be strongly considered by public mental health administrators. Yearly HIV testing among persons with severe mental illness could fit naturally with guideline-recommended metabolic screening for individuals taking antipsychotic medications.
Second, it is notable that use of nonpsychiatric outpatient medical care was the only modifiable factor that was associated with higher rates of HIV testing among adults with severe mental illness. This finding supports the importance of national efforts to integrate behavioral health and primary care, although we do not know whether increased comorbidity drove these nonpsychiatric medical care visits. Notably, many of the large primary and behavioral health care integration pilot programs funded by the Substance Abuse and Mental Health Services Administration found that access to primary care alone was not sufficient to improve general medical outcomes, and many of these programs were fiscally unsustainable (27). In addition, most of these programs narrowly focused on cardiovascular risk reduction (27,28). Given the high prevalence of HIV and other blood-borne infections among people with severe mental illness (3), we strongly suggest expanding the focus of efforts to integrate care beyond cardiovascular risk reduction to include HIV testing and expanding approaches to reducing high-risk sexual and drug use behaviors.
Individuals with severe mental illness have low rates of primary care utilization overall (29), but they do use community mental health clinics (30). Therefore, we believe that there is an opportunity to expand the scope of practice of community psychiatrists to take more responsibility for certain aspects of their patients’ medical care. We found that primary care providers and psychiatrists are at odds regarding who is responsible for conducting medical screening and treatment of this patient population, even when it comes to guideline-recommended metabolic testing (31,32). Because HIV testing is potentially more complicated and stigmatizing than metabolic testing, we believe that public mental health care system leaders should prioritize educating psychiatrists about the importance of HIV testing to reduce disease progression and transmission in this vulnerable population.
Finally, we found that rates of HIV testing differed among subgroups with severe mental illness; older adults, in particular, were much less likely to be tested for HIV. Eleven percent of new HIV infections occur among adults ages 50 and older, and older individuals are more likely to receive a diagnosis of HIV infection later in the course of the disease (29–31). These late diagnoses lead to impaired quality of life and reduced life expectancy in this population. Because 42% of our study participants were between age 48 and 67, a lack of prioritization of HIV testing in this age group constitutes another missed opportunity for prevention.
We also found low rates of HIV testing among Asians/Pacific Islanders, a finding consistent with other reports (33). Because Asians/Pacific Islanders are the only racial-ethnic group to experience an increase in HIV/AIDS diagnosis in recent years and studies indicate that testing rates increase if testing sites are culturally appropriate and testing is provided in a safe environment (34), this appears to be another missed prevention opportunity. Our findings that black participants and persons with comorbid substance use disorders were more likely to be tested for HIV suggest that clinicians are appropriately targeting screening efforts to some subpopulations at highest risk of HIV infection. However, the fact that HIV testing rates for blacks and persons with comorbid substance use disorders were only 10.8% and 9.6%, respectively, suggests that there is still significant room for improvement among these high-risk populations.
The major limitation of this study was our reliance on a large administrative database, including the CSI data submitted by counties to track mental health service utilization (14). Because dually eligible (Medicaid and Medicare) patients were not included, HIV testing rates may not reflect the population with severe mental illness as a whole, especially those over age 65. Extrapolation to newly enrolled patients may also be limited. In addition, HIV testing that was not billed to Medicaid (for example, bundled with other services during an inpatient hospital admission) was not captured, which could have led to an underestimation of screening rates.
Generalizability is a concern with use of databases with claims from a single state. In addition, the lack of a control group made direct comparisons challenging. We could not determine whether HIV testing was performed for people with a preexisting HIV infection, because we were not provided with HIV-related ICD-9 diagnosis codes. This decision was made by the Data and Research Committee of the California DHCS in an effort to avoid threatening the confidentiality of persons in rural counties. In addition, prescription claims for antipsychotic medications were used to define the cohort for a parent study examining diabetes screening (16). Therefore, we were unable to examine HIV testing of people with severe mental illness who received services at specialty mental health facilities and who were not taking these medications. Finally, although we were able to explore the role that substance use plays in driving HIV testing, this data set did not include sexual orientation, making it impossible to evaluate subpopulations that might most benefit from HIV testing (for example, men who have sex with men).

Conclusions

Our findings suggest that even after three decades of efforts to increase HIV testing in the United States, primary care physicians and psychiatrists are in need of more comprehensive education about the importance of HIV testing among persons with severe mental illness. Future research should be conducted to evaluate patient-, provider-, and system-level factors that might influence HIV testing. For example, these studies could explore factors that may contribute to this quality gap, such as patient refusal, stigma around HIV testing (both at patient and provider levels), and lack of psychiatrist education about HIV prevalence in populations with severe mental illness. Furthermore, mental health care teams’ practice of prioritizing psychosocial problems over medical screening and the lack of systemic infrastructure to facilitate HIV testing should be addressed. Policies or practices that might exempt mental health facilities from following guidelines recommended for all health care facilities should be discouraged. In addition, it is important to investigate whether HIV testing is more frequently ordered by psychiatrists or primary care providers.
Future studies must also focus on evidence-based efforts to increase HIV testing and linkage to care for people with severe mental illness. Although a recent systematic review found equivalent adherence to HIV/AIDS treatment guidelines among adults with severe mental illness and the general population, the results were limited by the paucity of such data (22). Although we recognize that longitudinal examination of HIV treatment among individuals with comorbid severe mental illness and HIV has been challenging because of the segregation of mental health and general medical care records in the public health system, we believe that evaluating the HIV care that this population receives—or does not receive—is another important area for future research.
In summary, we found a highly concerning lack of HIV testing among people with severe mental illness served in the public specialty mental health care system. Lack of HIV testing is a missed prevention opportunity and ultimately increases the risk of HIV transmission and delays treatment for those who have been infected, resulting in increased morbidity and mortality. The high-risk population of people with severe mental illness must be prioritized for any HIV testing initiative. Because most people with severe mental illness in the United States receive care in public specialty mental health clinics (30,35), we encourage public mental health administrators to expand their current efforts to integrate care beyond cardiovascular risk reduction to develop multilevel interventions to improve HIV testing in their systems of care.

Acknowledgments

The authors acknowledge CalMEND staff for their assistance in combining administrative databases. They also thank Martha Shumway, Ph.D., for performing initial data cleaning and coding and Nicholas S. Riano for preparation of the manuscript.

Supplementary Material

File (appi.ps.201600248.ds001.pdf)
File (appi.ps.201600248.ds002.pdf)

References

1.
Olfson M, Gerhard T, Huang C, et al: Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72:1172–1181, 2015
Crossref
PubMed
Google Scholar
2.
Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 3:A42, 2006
PubMed
Google Scholar
3.
Bermingham SL, Hughes R, Fenu E, et al: Cost-effectiveness analysis of alternative antiviral strategies for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B in the United Kingdom. Value in Health 18:800–809, 2015
Crossref
PubMed
Google Scholar
4.
Janssen EM, McGinty EE, Azrin ST, et al: Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. General Hospital Psychiatry 37:199–222, 2015
Crossref
PubMed
Google Scholar
5.
Meade CS, Sikkema KJ: Voluntary HIV testing among adults with severe mental illness: frequency and associated factors. AIDS and Behavior 9:465–473, 2005
Crossref
PubMed
Google Scholar
6.
McKinnon K, Cournos F, Herman R: HIV among people with chronic mental illness. Psychiatric Quarterly 73:17–31, 2002
Crossref
PubMed
Google Scholar
7.
Hobkirk AL, Towe SL, Lion R, et al: Primary and secondary HIV prevention among persons with severe mental illness: recent findings. Current HIV/AIDS Reports 12:406–412, 2015
Crossref
PubMed
Google Scholar
8.
Prince JD, Walkup J, Akincigil A, et al: Serious mental illness and risk of new HIV/AIDS diagnoses: an analysis of Medicaid beneficiaries in eight states. Psychiatric Services 63:1032–1038, 2012
Crossref
PubMed
Google Scholar
9.
Senn TE, Carey MP: HIV testing among individuals with a severe mental illness: review, suggestions for research, and clinical implications. Psychological Medicine 39:355–363, 2009
Crossref
PubMed
Google Scholar
10.
Yehia BR, Cui W, Thompson WW, et al: HIV testing among adults with mental illness in the United States. AIDS Patient Care and STDs 28:628–634, 2014
Crossref
PubMed
Google Scholar
11.
Mauer BJ, Druss BG: Mind and body reunited: improving care at the behavioral and primary healthcare interface. Journal of Behavioral Health Services and Research 37:529–542, 2010
Crossref
PubMed
Google Scholar
12.
HIV Among African Americans. Atlanta, Centers for Disease Control and Prevention, 2011
Google Scholar
13.
HIV Among Latinos. Atlanta, Centers for Disease Control and Prevention, 2011
Google Scholar
14.
Gilmer TP, Stefancic A, Tsemberis S, et al: Full-service partnerships among adults with serious mental illness in California: impact on utilization and costs. Psychiatric Services 65:1120–1125, 2014
Crossref
PubMed
Google Scholar
15.
Medi-Cal Program Enrollment Totals for Fiscal Year 2010–2011. Sacramento, California Department of Health Care Services, 2011
Google Scholar
16.
Mangurian C, Newcomer JW, Vittinghoff E, et al: Diabetes screening among underserved adults with severe mental illness who take antipsychotic medications. JAMA Internal Medicine 175:1977–1979, 2015
Crossref
PubMed
Google Scholar
17.
Key Policy Areas. Sacramento, County Behavioral Health Directors Association of California, 2014
Google Scholar
18.
Moyer VA: Screening for HIV: US Preventive Services Task Force recommendation statement. Annals of Internal Medicine 159:51–60, 2013
Crossref
PubMed
Google Scholar
19.
Ingram DD, Franco SJ: 2013 NCHS Urban-Rural Classification Scheme for Counties. Vital and Health Statistics, series 2, no 166. Atlanta, Centers for Disease Control and Prevention, National Center for Health Statistics, 2014. http://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf
Google Scholar
20.
Zou G: A modified Poisson regression approach to prospective studies with binary data. American Journal of Epidemiology 159:702–706, 2004
Crossref
PubMed
Google Scholar
21.
Centers for Disease Control and Prevention (CDC): Behavioral Risk Factor Surveillance System Data. Atlanta, Georgia, US Department of Health and Human Services, Centers for Disease Control and Prevention, 2012
Google Scholar
22.
McGinty EE, Baller J, Azrin ST, et al: Quality of medical care for persons with serious mental illness: a comprehensive review. Schizophrenia Research 165:227–235, 2015
Crossref
PubMed
Google Scholar
23.
Stefan MS, Blackwell JM, Crawford KM, et al: Patients’ attitudes toward and factors predictive of human immunodeficiency virus testing of academic medical clinics. American Journal of the Medical Sciences 340:264–267, 2010
Crossref
PubMed
Google Scholar
24.
Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings, 2006. MMWR 55:1–17, 2006
PubMed
Google Scholar
25.
Mahler J, Yi D, Sacks M, et al: Undetected HIV infection among patients admitted to an alcohol rehabilitation unit. American Journal of Psychiatry 151:439–440, 1994
Crossref
PubMed
Google Scholar
26.
Horwath E, Cournos F, McKinnon K, et al: Illicit-drug injection among psychiatric patients without a primary substance use disorder. Psychiatric Services 47:181–185, 1996
Crossref
PubMed
Google Scholar
27.
Scharf DM, Hackbarth NS, Horvitz-Lennon M, et al: Evaluation of the SAMHSA Primary and Behavioral Health Care Integration (PBHCI) Grant Program: Final Report. Santa Monica, Calif, RAND, 2013
Google Scholar
28.
McGinty EE, Baller J, Azrin ST, et al: Interventions to address medical conditions and health-risk behaviors among persons with serious mental illness: a comprehensive review. Schizophrenia Bulletin 42:96–124, 2016
PubMed
Google Scholar
29.
Annual Number and Percent Distribution of Ambulatory Care Visits by Setting Type According to Diagnosis Group. Atlanta, Centers for Disease Control and Prevention, 2015
Google Scholar
30.
Druss BG, Marcus SC, Campbell J, et al: Medical services for clients in community mental health centers: results from a national survey. Psychiatric Services 59:917–920, 2008
Crossref
PubMed
Google Scholar
31.
Parameswaran SG, Chang C, Swenson AK, et al: Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists. Schizophrenia Research 143:395–396, 2013
Crossref
PubMed
Google Scholar
32.
Mangurian C, Giwa F, Shumway M, et al: Primary care providers’ views on metabolic monitoring of outpatients taking antipsychotic medication. Psychiatric Services 64:597–599, 2013
Crossref
PubMed
Google Scholar
33.
Do TD, Chen S, McFarland W, et al: HIV testing patterns and unrecognized HIV infection among young Asian and Pacific Islander men who have sex with men in San Francisco. AIDS Education and Prevention 17:540–554, 2005
Crossref
PubMed
Google Scholar
34.
Do TD, Hudes ES, Proctor K, et al: HIV testing trends and correlates among young Asian and Pacific Islander men who have sex with men in two US cities. AIDS Education and Prevention 18:44–55, 2006
Crossref
PubMed
Google Scholar
35.
Khaykin E, Eaton WW, Ford DE, et al: Health insurance coverage among persons with schizophrenia in the United States. Psychiatric Services 61:830–834, 2010
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services

Cover: Untitled, by Sam Francis, 1958. Watercolor on paper. Gift of Udo M. Reinach Estate, The Museum of Modern Art, New York City. ©2017 Sam Francis Foundation, California/Artists Rights Society, New York City. Digital image © The Museum of Modern Art/licensed by SCALA/Art Resource, New York City.

Psychiatric Services
Volume 68 • Number 5 • May 01, 2017
Pages: 443 - 448
PubMed: 28093055

History

Received: 1 June 2016
Revision received: 30 August 2016
Accepted: 7 October 2016
Published online: 17 January 2017
Published in print: May 01, 2017

Keywords

  1. AIDS
  2. Community mental health services
  3. Quality of care
  4. Research/service delivery
  5. Schizophrenia

Authors

Details

Christina Mangurian, M.D., M.A.S.
Dr. Mangurian, Mr. Lee, and Dr. Dilley are with the Department of Psychiatry and the Weill Institute for Neurosciences; Dr. Schillinger is with the Department of Medicine; Dr. Vittinghoff is with the Department of Epidemiology and Biostatistics; Ms. Creasman is with the Clinical and Translational Science Institute (CTSI); and Dr. Fuentes-Afflick is with the Department of Pediatrics, all at the School of Medicine, University of California, San Francisco (UCSF) (e-mail: [email protected]). Dr. Mangurian, Dr. Schillinger, Dr. Fuentes-Afflick, and Dr. Dilley are also with Zuckerberg San Francisco General Hospital, San Francisco. Dr. Cournos is with the Department of Psychiatry, Columbia University, New York City. Dr. Knapp is with the Department of Psychiatry and Behavioral Sciences, University of California, Davis.
View all articles by this author
Francine Cournos, M.D.
Dr. Mangurian, Mr. Lee, and Dr. Dilley are with the Department of Psychiatry and the Weill Institute for Neurosciences; Dr. Schillinger is with the Department of Medicine; Dr. Vittinghoff is with the Department of Epidemiology and Biostatistics; Ms. Creasman is with the Clinical and Translational Science Institute (CTSI); and Dr. Fuentes-Afflick is with the Department of Pediatrics, all at the School of Medicine, University of California, San Francisco (UCSF) (e-mail: [email protected]). Dr. Mangurian, Dr. Schillinger, Dr. Fuentes-Afflick, and Dr. Dilley are also with Zuckerberg San Francisco General Hospital, San Francisco. Dr. Cournos is with the Department of Psychiatry, Columbia University, New York City. Dr. Knapp is with the Department of Psychiatry and Behavioral Sciences, University of California, Davis.
View all articles by this author
Dean Schillinger, M.D.
Dr. Mangurian, Mr. Lee, and Dr. Dilley are with the Department of Psychiatry and the Weill Institute for Neurosciences; Dr. Schillinger is with the Department of Medicine; Dr. Vittinghoff is with the Department of Epidemiology and Biostatistics; Ms. Creasman is with the Clinical and Translational Science Institute (CTSI); and Dr. Fuentes-Afflick is with the Department of Pediatrics, all at the School of Medicine, University of California, San Francisco (UCSF) (e-mail: [email protected]). Dr. Mangurian, Dr. Schillinger, Dr. Fuentes-Afflick, and Dr. Dilley are also with Zuckerberg San Francisco General Hospital, San Francisco. Dr. Cournos is with the Department of Psychiatry, Columbia University, New York City. Dr. Knapp is with the Department of Psychiatry and Behavioral Sciences, University of California, Davis.
View all articles by this author
Eric Vittinghoff, Ph.D.
Dr. Mangurian, Mr. Lee, and Dr. Dilley are with the Department of Psychiatry and the Weill Institute for Neurosciences; Dr. Schillinger is with the Department of Medicine; Dr. Vittinghoff is with the Department of Epidemiology and Biostatistics; Ms. Creasman is with the Clinical and Translational Science Institute (CTSI); and Dr. Fuentes-Afflick is with the Department of Pediatrics, all at the School of Medicine, University of California, San Francisco (UCSF) (e-mail: [email protected]). Dr. Mangurian, Dr. Schillinger, Dr. Fuentes-Afflick, and Dr. Dilley are also with Zuckerberg San Francisco General Hospital, San Francisco. Dr. Cournos is with the Department of Psychiatry, Columbia University, New York City. Dr. Knapp is with the Department of Psychiatry and Behavioral Sciences, University of California, Davis.
View all articles by this author
Jennifer M. Creasman, M.S.P.H.
Dr. Mangurian, Mr. Lee, and Dr. Dilley are with the Department of Psychiatry and the Weill Institute for Neurosciences; Dr. Schillinger is with the Department of Medicine; Dr. Vittinghoff is with the Department of Epidemiology and Biostatistics; Ms. Creasman is with the Clinical and Translational Science Institute (CTSI); and Dr. Fuentes-Afflick is with the Department of Pediatrics, all at the School of Medicine, University of California, San Francisco (UCSF) (e-mail: [email protected]). Dr. Mangurian, Dr. Schillinger, Dr. Fuentes-Afflick, and Dr. Dilley are also with Zuckerberg San Francisco General Hospital, San Francisco. Dr. Cournos is with the Department of Psychiatry, Columbia University, New York City. Dr. Knapp is with the Department of Psychiatry and Behavioral Sciences, University of California, Davis.
View all articles by this author
Bernard Lee, M.P.H.
Dr. Mangurian, Mr. Lee, and Dr. Dilley are with the Department of Psychiatry and the Weill Institute for Neurosciences; Dr. Schillinger is with the Department of Medicine; Dr. Vittinghoff is with the Department of Epidemiology and Biostatistics; Ms. Creasman is with the Clinical and Translational Science Institute (CTSI); and Dr. Fuentes-Afflick is with the Department of Pediatrics, all at the School of Medicine, University of California, San Francisco (UCSF) (e-mail: [email protected]). Dr. Mangurian, Dr. Schillinger, Dr. Fuentes-Afflick, and Dr. Dilley are also with Zuckerberg San Francisco General Hospital, San Francisco. Dr. Cournos is with the Department of Psychiatry, Columbia University, New York City. Dr. Knapp is with the Department of Psychiatry and Behavioral Sciences, University of California, Davis.
View all articles by this author
Penelope Knapp, M.D.
Dr. Mangurian, Mr. Lee, and Dr. Dilley are with the Department of Psychiatry and the Weill Institute for Neurosciences; Dr. Schillinger is with the Department of Medicine; Dr. Vittinghoff is with the Department of Epidemiology and Biostatistics; Ms. Creasman is with the Clinical and Translational Science Institute (CTSI); and Dr. Fuentes-Afflick is with the Department of Pediatrics, all at the School of Medicine, University of California, San Francisco (UCSF) (e-mail: [email protected]). Dr. Mangurian, Dr. Schillinger, Dr. Fuentes-Afflick, and Dr. Dilley are also with Zuckerberg San Francisco General Hospital, San Francisco. Dr. Cournos is with the Department of Psychiatry, Columbia University, New York City. Dr. Knapp is with the Department of Psychiatry and Behavioral Sciences, University of California, Davis.
View all articles by this author
Elena Fuentes-Afflick, M.D., M.P.H.
Dr. Mangurian, Mr. Lee, and Dr. Dilley are with the Department of Psychiatry and the Weill Institute for Neurosciences; Dr. Schillinger is with the Department of Medicine; Dr. Vittinghoff is with the Department of Epidemiology and Biostatistics; Ms. Creasman is with the Clinical and Translational Science Institute (CTSI); and Dr. Fuentes-Afflick is with the Department of Pediatrics, all at the School of Medicine, University of California, San Francisco (UCSF) (e-mail: [email protected]). Dr. Mangurian, Dr. Schillinger, Dr. Fuentes-Afflick, and Dr. Dilley are also with Zuckerberg San Francisco General Hospital, San Francisco. Dr. Cournos is with the Department of Psychiatry, Columbia University, New York City. Dr. Knapp is with the Department of Psychiatry and Behavioral Sciences, University of California, Davis.
View all articles by this author
James W. Dilley, M.D.
Dr. Mangurian, Mr. Lee, and Dr. Dilley are with the Department of Psychiatry and the Weill Institute for Neurosciences; Dr. Schillinger is with the Department of Medicine; Dr. Vittinghoff is with the Department of Epidemiology and Biostatistics; Ms. Creasman is with the Clinical and Translational Science Institute (CTSI); and Dr. Fuentes-Afflick is with the Department of Pediatrics, all at the School of Medicine, University of California, San Francisco (UCSF) (e-mail: [email protected]). Dr. Mangurian, Dr. Schillinger, Dr. Fuentes-Afflick, and Dr. Dilley are also with Zuckerberg San Francisco General Hospital, San Francisco. Dr. Cournos is with the Department of Psychiatry, Columbia University, New York City. Dr. Knapp is with the Department of Psychiatry and Behavioral Sciences, University of California, Davis.
View all articles by this author

Competing Interests

The authors report no financial relationships with commercial interests.

Funding Information

National Center on Minority Health and Health Disparities10.13039/100000096: P60MD006902
National Institute of Diabetes and Digestive and Kidney Diseases10.13039/100000062: P30DK092924-01
National Institutes of Health10.13039/100000002: K23MH093689
National Institute of Mental Health10.13039/100000025: P30MH43520
National Center for Advancing Translational Sciences10.13039/100006108: UL1TR000004
Health Resources and Services Administration10.13039/100000102: U1OHA29291
Dr. Mangurian is supported by Career Development Award K23MH093689 from the National Institutes of Health (NIH), the UCSF Hellman Fellows Award for Early-Career Faculty, and the UCSF San Francisco General Hospital Department of Psychiatry. Dr. Schillinger and Dr. Fuentes-Afflick are supported by a National Institute on Minority Health and Health Disparities center grant (P60MD006902). Dr. Schillinger is also supported by a National Institute of Diabetes and Digestive and Kidney Diseases center grant (P30DK092924-01). This study was initiated during a state quality improvement project to integrate primary care and mental health care called the California Mental Health Care Management Program (CalMEND). The project was a collaboration between the California Department of Mental Health and the Pharmacy Benefits Division of Health Care Services.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Item saved, go to cart
Purchase Options

Purchase this article to access the full text.

PPV Articles - Psychiatric Services

PPV Articles - Psychiatric Services

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.